Fatty liver symptoms in females are often subtle or absent in the early stages, making the condition easy to overlook. Fatty liver disease — particularly metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as NAFLD — affects an estimated one in three UK adults and carries distinct risks for women. Hormonal factors, including the menopause and polycystic ovary syndrome (PCOS), influence how fat accumulates in the liver and how symptoms present. Understanding the signs, risk factors, and when to seek NHS assessment is essential for early intervention, when the condition is most reversible.

What Is Fatty Liver Disease and Who Does It Affect?

Fatty liver disease involves excess fat accumulating in liver cells; MASLD is the most common form in the UK, affecting around one in three adults and carrying particular risk for post-menopausal women and those with PCOS.

Fatty liver disease is a condition in which excess fat accumulates within liver cells. There are two principal forms: alcohol-related liver disease (ARLD), which includes alcohol-related fatty liver (steatosis) linked to heavy alcohol consumption, and metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as non-alcoholic fatty liver disease (NAFLD) — which occurs independently of alcohol intake. MASLD is now the preferred term used by leading hepatology bodies, including the European Association for the Study of the Liver (EASL); however, NHS and NICE guidance (including NICE NG49) continue to use the term NAFLD in many materials, and both terms may be encountered in clinical settings.

MASLD is one of the most common liver conditions in the UK, affecting an estimated one in three adults to some degree (NHS). It is closely associated with:

• Obesity or being overweight, particularly central (abdominal) adiposity

• Type 2 diabetes and insulin resistance

• High cholesterol or triglycerides (dyslipidaemia)

• Metabolic syndrome

Risk is also higher in certain ethnic groups, including people of South Asian heritage, who are more likely to develop metabolic risk factors at a lower body mass index.

While fatty liver disease can affect anyone, it is increasingly recognised that women — particularly those who are post-menopausal or living with polycystic ovary syndrome (PCOS) — face a distinct and often underappreciated risk. Hormonal changes across a woman's lifetime, including fluctuations in oestrogen, appear to influence how fat is stored and metabolised in the liver. In its early stages, fatty liver disease is generally reversible with lifestyle changes, making early recognition especially important.

Common Fatty Liver Symptoms in Women

Fatty liver disease is often asymptomatic, but women may experience persistent fatigue, upper right abdominal discomfort, and nausea; advanced disease can cause jaundice, swelling, and bleeding requiring urgent attention.

One of the most clinically significant features of fatty liver disease is that it is frequently asymptomatic in its early stages. Many women are diagnosed incidentally — for example, when a routine blood test reveals elevated liver enzymes, or when an ultrasound performed for another reason identifies a bright or enlarged liver.

When symptoms do occur, they tend to be non-specific and easy to attribute to other conditions. Women with fatty liver disease may experience:

• Persistent fatigue or low energy, often described as feeling unusually tired despite adequate rest

• A dull, aching discomfort in the upper right abdomen, where the liver is located

• Nausea or a general sense of feeling unwell

Some women also report difficulty concentrating, though it is important to note that this is a non-specific symptom with limited evidence linking it directly to fatty liver disease, and it may reflect other underlying conditions.

As the condition progresses to a more advanced stage — known as metabolic dysfunction-associated steatohepatitis (MASH), or previously non-alcoholic steatohepatitis (NASH) — inflammation and liver cell damage occur. If left unmanaged, this can lead to fibrosis (scarring) and ultimately cirrhosis. At this stage, more serious symptoms may emerge, including:

• Jaundice (yellowing of the skin or whites of the eyes)

• Swollen ankles or abdomen

• Easy bruising or unusual bleeding

• Vomiting blood or passing black, tarry stools (which require urgent medical attention)

• Confusion or increasing sleepiness (which may indicate hepatic encephalopathy and also requires urgent assessment)

It is important to note that these advanced symptoms are not exclusive to fatty liver disease and always warrant prompt medical assessment.

Why Symptoms May Differ Between Women and Men

Oestrogen protects against hepatic fat accumulation before the menopause, but this protection diminishes afterwards; women with PCOS face elevated risk at any age due to insulin resistance and raised androgens.

Emerging research suggests that sex-based biological differences influence both the development and presentation of fatty liver disease. Oestrogen plays a role in liver fat metabolism, which may partly explain why pre-menopausal women tend to have a lower prevalence of MASLD compared to men of the same age. However, this relative protection diminishes after the menopause, when oestrogen levels fall and the risk of developing fatty liver disease rises — a pattern supported by European and international epidemiological data (EASL–EASD–EASO consensus).

Women with polycystic ovary syndrome (PCOS) are at particularly elevated risk, even when young. PCOS is associated with insulin resistance and elevated androgens, both of which promote hepatic fat accumulation. Research suggests that women with PCOS have a significantly increased risk of fatty liver disease compared to women without the condition, though the precise magnitude of risk varies across studies (ESHRE PCOS guideline; NHS PCOS information).

Symptom perception may also differ. Women are more likely to report fatigue, abdominal discomfort, and nausea as prominent features — symptoms that can overlap considerably with conditions such as irritable bowel syndrome (IBS), thyroid disorders, or perimenopause. This overlap can contribute to diagnostic delay. Clinicians are encouraged to consider metabolic risk factor screening in all women, regardless of alcohol history, particularly those with obesity, PCOS, or type 2 diabetes.

When to Seek Medical Advice and What to Expect on the NHS

Women with persistent fatigue, upper right abdominal discomfort, or metabolic risk factors should see their GP promptly; vomiting blood or confusion requires urgent emergency assessment.

Women who experience persistent, unexplained fatigue or discomfort in the upper right abdomen, or who have known risk factors such as obesity, type 2 diabetes, or PCOS, should speak to their GP. It is not necessary to wait for severe symptoms before seeking advice — early assessment is strongly encouraged, as fatty liver disease is most amenable to intervention before significant fibrosis develops.

Contact your GP promptly if you notice:

• Yellowing of the skin or whites of the eyes (jaundice)

• Significant, unexplained weight loss

• Persistent nausea or vomiting

• Swelling of the abdomen or ankles

• Unusual bruising or bleeding

Seek urgent medical attention if you experience:

• Vomiting blood or passing black, tarry stools

• Confusion, increasing sleepiness, or difficulty staying awake

On the NHS, your GP will typically begin with a clinical history and examination, followed by blood tests to assess liver function. In line with NICE guidance (NG49) and BSG/BASL primary care pathways, your GP may use the FIB-4 score (based on age, liver enzymes, and platelet count) as an initial non-invasive tool to estimate the likelihood of significant liver fibrosis. Where results suggest intermediate or higher risk, the Enhanced Liver Fibrosis (ELF) test — recommended by NICE (Diagnostics Guidance DG34) — may be used to further assess advanced fibrosis before referral decisions are made. NICE guidance (NG49) recommends that people with NAFLD/MASLD and suspected advanced fibrosis are referred to a specialist hepatology or gastroenterology service. Your GP can also provide guidance on lifestyle modifications and, where appropriate, refer you to a dietitian or structured weight management programme.

Diagnosis and Tests Used to Assess Liver Health in the UK

Diagnosis combines liver function tests, FIB-4 scoring, and the NICE-recommended ELF test; ultrasound detects steatosis but cannot reliably stage fibrosis, and liver biopsy is reserved for uncertain cases.

Diagnosing fatty liver disease involves a combination of blood tests, imaging, and sometimes specialist assessment. There is no single definitive test, and diagnosis is typically made by excluding other causes of liver disease alongside clinical and biochemical findings.

Common investigations include:

• Liver function tests (LFTs): Elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may indicate liver inflammation, though normal LFTs do not exclude fatty liver disease

• Fasting lipid profile and HbA1c: To assess for dyslipidaemia and diabetes, which are closely linked to MASLD

• FIB-4 score: A non-invasive calculation widely used in UK primary care (per BSG/BASL guidance) to stratify fibrosis risk as an initial step

• Enhanced Liver Fibrosis (ELF) test: Recommended by NICE (DG34) for assessing advanced fibrosis, typically used when FIB-4 results are intermediate or when further stratification is needed before specialist referral

• Liver ultrasound: A widely available, non-invasive imaging tool that can detect increased echogenicity (brightness) consistent with hepatic steatosis; however, it has reduced sensitivity in mild steatosis and in people with obesity, and cannot reliably stage fibrosis

• FibroScan (transient elastography): Used in secondary care to measure liver stiffness, providing a non-invasive estimate of fibrosis stage; it assesses stiffness rather than fat content directly

• Liver biopsy: Reserved for cases where the diagnosis is uncertain or where the degree of fibrosis needs precise characterisation; it remains the reference standard but carries procedural risks

Tests to exclude other causes of liver disease are an important part of the work-up and typically include:

• Hepatitis B surface antigen (HBsAg) and hepatitis C antibody/antigen testing

• Autoimmune liver disease screen (antinuclear antibody [ANA], smooth muscle antibody [SMA], anti-mitochondrial antibody [AMA], immunoglobulins) — primary biliary cholangitis (PBC) is more common in women and should be considered

• Ferritin and iron studies (to assess for haemochromatosis or iron overload)

• Thyroid function tests and coeliac serology, both of which can cause elevated liver enzymes and are more prevalent in women

Clinicians are increasingly encouraged to consider hormonal and reproductive history — including menopausal status and PCOS — as part of a holistic assessment.

Managing Fatty Liver Disease: Lifestyle and Treatment Options

Lifestyle modification — including 5–10% weight loss and a Mediterranean-style diet — is the cornerstone of MASLD management, as no medicines are currently licensed specifically for this condition in the UK.

The cornerstone of managing fatty liver disease — particularly MASLD — remains lifestyle modification. There are currently no medicines licensed specifically for the treatment of MASLD in the UK. NICE guidance (NG49) does note that, in specialist care, pioglitazone or vitamin E may be considered in selected adults with biopsy-confirmed MASH (NASH), but only under specialist supervision and with careful consideration of individual risks and contraindications; these are not routinely recommended in primary care.

Key lifestyle recommendations include:

• Weight loss: Even a modest reduction of 5–10% of body weight has been shown to significantly reduce hepatic fat content and inflammation. A loss of 10% or more may lead to regression of fibrosis in some patients

• Dietary changes: A Mediterranean-style diet — rich in vegetables, wholegrains, legumes, fish, and olive oil, and low in refined sugars and saturated fats — is widely supported by evidence

• Physical activity: Both aerobic exercise and resistance training have demonstrated benefit in reducing liver fat, independent of weight loss. UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults

• Alcohol: UK Chief Medical Officers' low-risk drinking guidelines advise consuming no more than 14 units of alcohol per week, spread across several days, with several alcohol-free days each week. For those with significant fibrosis or cirrhosis, abstinence from alcohol is advisable; discuss this with your GP or specialist

• Management of metabolic comorbidities: Optimising blood glucose control, treating dyslipidaemia, and managing hypertension are all integral to reducing liver disease progression. Statins are safe to use in MASLD/NAFLD and should be prescribed when indicated to manage cardiovascular risk, which is elevated in this population

For women with PCOS or type 2 diabetes, metformin may be prescribed for those indications when clinically appropriate. It is important to note that metformin is not recommended by NICE as a treatment for NAFLD/MASLD itself, and should not be used solely with the aim of treating liver disease.

Follow-up and monitoring should be guided by individual risk, using non-invasive fibrosis assessment tools (such as the ELF test) at intervals determined by your clinical team and local pathway, rather than routine annual imaging for all patients. Any changes in symptoms or test results should prompt timely review.

If you are taking any medicines and experience unexpected side effects, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions